Represents the percentage of royalty payments receivable under collaboration arrangement.

No definition available.

Name:	tbph_ContingentConsiderationPercentageOfRoyaltyPaymentsReceivable
Namespace Prefix:	tbph_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of milestone payments receivable from contingent consideration in a business combination.

+ References

No definition available.

+ Details

Name:	tbph_ContingentConsiderationPotentialMilestonePaymentsReceivable
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Value of input used to measure equity method investment, contingent consideration.

+ References

No definition available.

+ Details

Name:	tbph_EquityMethodInvestmentContingentConsiderationMeasurementInput
Namespace Prefix:	tbph_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of future contingent milestone and royally assets.

+ References

No definition available.

+ Details

Name:	tbph_FutureContingentMilestoneAndRoyaltyAssets
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of cash inflow associated with milestone and royalty assets.

+ References

No definition available.

+ Details

Name:	tbph_ProceedsFromMilestoneAndRoyaltyAssets
Namespace Prefix:	tbph_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

+ Details

Name:	us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_CounterpartyNameAxis=tbph_RoyaltyPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Investments and Fair Value Measurements - Contingent Consideration Asset (Details) $ in Thousands	1 Months Ended	3 Months Ended
	Feb. 28, 2025 USD ($)	Mar. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Jul. 31, 2022 USD ($)
Theravance Respiratory Company, LLC
Future contingent milestone and royalty assets		$ 144,200	$ 144,200
Royalty Pharma
Theravance Respiratory Company, LLC
Payments receivable		$ 150,000
Percentage of royalty payments receivable		85.00%
Future contingent milestone and royalty assets		$ 144,200		$ 194,200
Proceeds from milestone and royalty assets	$ 50,000
Royalty Pharma \| Maximum
Theravance Respiratory Company, LLC
Payments receivable		$ 250,000
Royalty Pharma \| Measurement Input, Discount Rate [Member]
Theravance Respiratory Company, LLC
Contingent consideration measurement input				0.0783